Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australia To Address Supply Chain Issues In Medicines Access Review

Policy May Be Extended To Vaccines & Devices

Executive Summary

Stakeholders are being asked to say what they think of plans to future-proof the framework that governs access to medicines and is intended to help bolster the pharmaceutical sector.

You may also be interested in...



Australian Industry Signs Deal To Fund Access To Innovative New Drugs

Hot on the heels of Australia’s plan to overhaul the National Medicines Policy comes a new deal with the pharmaceutical industry to make new drugs available as soon as possible after approval and get patients more closely involved in reimbursement processes.

Australia Launches Review Into Medicines Access & Affordability

Time has taken its toll on Australia’s National Medicines Policy since it was implemented in 2000.

Drug Over-Use & Industry’s Carbon Footprint Targeted In English Review

New recommendations could result in more effective prescribing and fewer adverse events.

Topics

UsernamePublicRestriction

Register

PS144901

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel